A PHASE 2 STUDY OF ALKS 4230 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED OR RECURRENT HEAD AND NECK SQUAMOUS CELL CANCER CURRENTLY ON TREATENT WITH ANTI-PD-(L)1 WITHOUT HAVING ACHIEVED A COMPLETE REMISSION
Brief description of study
The purpose of this study is to see how well ALKS 4230 (IL-2 and IL-2 receptor (R; IL-2R)) works together with the drug Prembrolizumab to treat advanced or recurrent head and neck cancer in people who have not responded to other Immune-targeted treatment. Additionally, to learn how long any responses to the combination of ALKS 4230 and Pembrolizumab last. Also, if there are side effects caused by ALKS 4230 given together with pembrolizumab in this setting and how well the body responds to it.
Clinical Study Identifier: s19-00231
ClinicalTrials.gov Identifier: NCT04144517
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
